IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.
Company: Tonix Pharmaceuticals
Symbol: TNXP
Price: Last trade $8.22
Trade Date: 7/14
Shares: TBD
Underwriter(s) Roth Capital Partners, Oppenheimer & Co.
Co Manager(s) Janney Montgomery Scott
Rating=Subscription Needed
Company: MacroGenics, Inc.
Symbol: MGNX
Price: Last trade $39.44
Trade Date: 7/15
Shares: 3.25 million
Underwriter(s) Morgan Stanley, Citigroup, Leerink Partners, Stifel
Rating=Subscription Needed
Company: NeuroDerm Ltd.
Symbol: NDRM
Price: Last trade $16.06
Trade Date: 7/16
Shares: 3.34 million
Underwriter(s) Jefferies, Cowen & Co.
Co Manager(s) Raymond James, Roth Capital Partners
Rating=Subscription Needed
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish